Affiliated with a Castle Connolly Top Hospital
Who is Dr. Telli, Medical Oncologist in Stanford, CA?
Castle Connolly Top Doctor
Castle Connolly Top Doctors are doctor-nominated and selected by a physician-led research team.
What are Areas of Expertise for Dr. Telli?
Dr. Melinda Telli, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Telli empowers patients to confidently navigate their health journey, specializing in Breast Cancer, Breast Cancer Genetics, Hereditary Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Telli is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Telli go to medical school and complete their residency?
Fellowship: Stanford University Medical Oncology | Stanford University School of Medicine CA | Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University, Internal Medicine | Stanford University Medical Center
Is Dr. Telli board certified as a Medical Oncologist?
Yes, Dr. Melinda Telli, MD is board certified by the American Board of Internal Medicine , American Board of Internal Medicine since 2008, American Board of Internal Medicine since 2005
What languages does Dr. Telli speak?
Dr. Telli and their clinical team can communicate with patients in the following languages:
- English
- Turkish
What conditions does a Medical Oncologist like Dr. Telli typically treat?
As a Medical Oncologist, Dr. Telli diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Telli. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Breast Cancer
- Female Breast Cancer
- Malignant Breast Tumor
- Breast Carcinoma
- Mammary cancer
- Breast carcinoma
- Breast tumor
ICD-10 Codes:
- C50919: Malignant neoplasm of unspecified site of unspecified female breast
- C50912: Malignant neoplasm of unspecified site of left female breast
- C50911: Malignant neoplasm of unspecified site of right female breast
Also known as:
- Personal History of Breast Cancer
- Breast Cancer
- Past breast cancer
- Previous mammary malignancy
- History of breast tumor
ICD-10 Codes:
- Z853: Personal history of malignant neoplasm of breast
Also known as:
- Secondary Bone Cancer
- Bone Cancer
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
ICD-10 Codes:
- C7951: Secondary malignant neoplasm of bone
What procedures does a Medical Oncologist like Dr. Telli typically perform?
As a Medical Oncologist, Dr. Telli performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Telli. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Does Dr. Telli accept my insurance?
Dr. Telli accepts most major insurance plans. Important: Please contact the office before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Telli accept in Stanford, CA?
Dr. Telli in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Kaiser Permanente
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
Valley Health Plan
View All Insurances
Where is Dr. Telli's office located?
What hospitals are Dr. Telli affiliated with?
Castle Connolly Top Hospital
This doctor is affiliated with a Castle Connolly Top Hospital.
Dr. Telli has admitting privileges at the following hospitals:
Recognitions
Awards
Career Catalyst Research Award – Susan G. Komen for the Cure, 2012
Oncology Division Teaching Award – Stanford University School of Medicine
Young Investigator Award – American Society of Clinical Oncology, 2009
Fellowship Award – Susan G. Komen for the Cure, 2008
Merit Award – American Society of Clinical Oncology, 2008
New Investigator Award – Stanford Cancer Institute, 2011
Publications
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer, 2013
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?, 2012
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians, 2010
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate, 2008
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility, 2007
Dymic contrast-enhanced MRI, 2013
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early, 2012
Single Cell Profiling of Circulating Tumor Cells, 2012
Prevalence, putative mechanisms, 2012
Trastuzumab-Related Cardiac Dysfunction, 2011
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California, 2010
Phyllodes tumors of the breast: tural history, diagnosis, and treatment., 2007
Epidermal growth factor, 1999
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer, 2013
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?, 2012
PARP inhibitors in cancer: moving beyond BRCA, 2011
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry, 2011
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians, 2010
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate, 2008
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility, 2007
Patient-derived xenografts of triple, 2014
(18)F-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients., 2014
Optimizing chemotherapy in triple-negative breast cancer: the role of platinum., 2014
Single cell mutational analysis of PIK3CA in circulating tumor cells, 2014
Dynamic contrast-enhanced MRI, 2013
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk, 2013
Qualitative and quantitative image-based biomarkers of therapeutic response in triple, 2013
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early, 2012
Breast cancer phenotype in women with TP53 germline mutations, 2012
Single Cell Profiling of Circulating Tumor Cells, 2012
Prevalence, putative mechanisms, 2012
Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?, 2011
Trastuzumab-Related Cardiac Dysfunction, 2011
PARP inhibitors in breast cancer., 2010
Novel Treatment Approaches for Triple-Negative Breast Cancer, 2010
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California, 2010
Longer Relative Telomere Length in Blood from Women with Sporadic, 2010
First-Line Chemotherapy for Metastatic Breast Cancer, 2009
Phyllodes tumors of the breast: natural history, diagnosis, and treatment., 2007
Epidermal growth factor, 1999
What is Dr. Telli's NPI number?A National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Telli's National Provider Identifier (NPI) number is 1932135290.
What common questions do patients ask about Dr. Telli?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Telli